

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/CD9B2FA9DFCEN.html>

Date: May 2018

Pages: 123

Price: US\$ 3,500.00 (Single User License)

ID: CD9B2FA9DFCEN

Abstracts

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'Cyclin Dependent Kinase 4 - Pipeline Review, H1 2018'; Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.

The report 'Cyclin Dependent Kinase 4 - Pipeline Review, H1 2018' outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 4, 2, 1, 9, 1 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Immunology and Toxicology which include indications Metastatic Breast Cancer, Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, Pancreatic Cancer, Bladder Cancer, Gastric Cancer, Colon Cancer, Esophageal Cancer, Glioblastoma Multiforme (GBM), Leukemias, Liposarcoma, Lymphoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Oligodendroglioma, Pancreatic Ductal Adenocarcinoma, Recurrent Glioblastoma Multiforme (GBM), Solid Tumor, Thymic Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), AIDS - Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, B-Cell Leukemia, Brain Tumor, Cervical Cancer, Chemotherapy Induced Myelosuppression, Chordoma, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Fallopian Tube Cancer, Germ Cell Tumors, Glioma, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Neuroendocrine Tumors, Nonmelanomatous Skin Cancer, Peritoneal Cancer, Primary CNS Lymphoma, Prostate Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Thymoma (Thymic Epithelial Tumor) and Unspecified B-Cell Lymphomas.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)

The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects

The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create

effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development

Beta Pharma Inc

Eli Lilly and Co

G1 Therapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

MetaMax Ltd

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Sihuan Pharmaceutical Holdings Group Ltd

Teijin Pharma Ltd

Tiziana Life Sciences Plc

ViroStatics srl

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles

abemaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BEBT-209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-1178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-1T38 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-381 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HEC-80797 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MMD-37K - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-123300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ribociclib succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-6390 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trilaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voruciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-2370 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-3287 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones

Featured News & Press Releases

May 02, 2018: Health Canada approves KISQALI for the treatment of HR-positive and HER2-negative metastatic breast cancer in postmenopausal women in combination with letrozole as an initial endocrine-based therapy

Apr 19, 2018: Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting

Apr 17, 2018: Positive results with DiviTum from new Pfizer study presented at the AACR congress

Apr 16, 2018: G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

Apr 09, 2018: Tiziana Life Sciences Announces a Poster Presentation on Phase II clinical data with Milciclib in Thymic carcinoma and Thymoma patients at the American Society of Clinical Oncology (ASCO) Meeting (June 1-5, Chicago IL)

Apr 09, 2018: G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitor Trilaciclib at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Apr 09, 2018: G1 Therapeutics to Present Preclinical Data on G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Mar 15, 2018: Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018

Mar 12, 2018: Novartis' Advanced Breast Cancer Drug Kisqali (ribociclib)

Recommended for NHS Funding in Scotland, Offering Women an Average of two Years without their Disease Getting Worse

Mar 12, 2018: Novartis's Kisqali accepted for use in NHS Scotland

Mar 05, 2018: G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits in Patients with Small Cell Lung Cancer

Mar 01, 2018: New blood test could quickly predict if the drug palbociclib will help breast cancer patients

Feb 26, 2018: Lilly Receives Additional FDA Approval for Verzenio (abemaciclib), as Initial Treatment for Advanced Breast Cancer

Feb 22, 2018: Leading US University Includes DiviTum in a New Study of Breast Cancer with Ibrance

Feb 15, 2018: Quebec and New Brunswick Become First Provinces to Provide Public Funding of IBRANCE for the First-Line Treatment of Metastatic Breast Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.3), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Products under Development by Companies, H1 2018 (Contd.5), H1 2018
Products under Development by Companies, H1 2018 (Contd.6), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Beta Pharma Inc, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by G1 Therapeutics Inc, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by MEI Pharma Inc, H1 2018
Pipeline by MetaMax Ltd, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Onconova Therapeutics Inc, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H1 2018
Pipeline by Teijin Pharma Ltd, H1 2018
Pipeline by Tiziana Life Sciences Plc, H1 2018
Pipeline by ViroStatics srl, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018

Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Beta Pharma Inc

Eli Lilly and Co

G1 Therapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

MetaMax Ltd

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Sihuan Pharmaceutical Holdings Group Ltd

Teijin Pharma Ltd

Tiziana Life Sciences Plc

ViroStatics srl

I would like to order

Product name: Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/CD9B2FA9DFCEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CD9B2FA9DFCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

